»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ *rS9eej
Dm7Y#)%8
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 9zXu6<|qrL
hu bfK~
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© 5}vRo;-
1.Antigen presenting cell£¨APC£©
N BV}4
2.Activation induced cell death£¨AICD£© M'pb8jf
3.Chemokine Gg
7WmL
4.Major histocompatibility complex£¨MHC£© *>H M$.?Q
5.immunotolerance l=oN X"l=
XkM s
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© AyQS4A.s[
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ ti$oZ4PpF
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà zvek2\*rO
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ 'Qm` A=
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ tIz<+T_
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã w.4u=e >Z4
oV0LJ%
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© [}W^4,
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ P<j4\zJ
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ Ze[g0"
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ K7t&fDI
Wrf^O2
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ uM6CG0
OqfhCNAY
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 jMm_A#V>p
J~_L4*Jw
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ 4*p_s8> >
1.Antigenic determinant _aXP
;kFMi
2.IgSF ?$"x^=te7
3.MBL;¾¶ ^@|<'g.R-
4.chemokine #}[Sj-Vp
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ 2.fyP"P
L
6.TCR-CD3¸´ºÏÎï 8!
|.H p
7.FADD£¨Fas-associated protein with death domain£© ZI2K-z'e
8.AIDS I3}HNGvU
9.Tumor rejection antigen J)7,&Gc6
10.AICD
rE1np^z7
Z/V`Z* fy
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ ;Zx K3/(7
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© \j2:
6]Hm
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ x*loACee.
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ Y0P}KPD
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì
Pqr Ou
yBYuDfeZ
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ K,lK\^y
`'G),{ j
s]nGpA[!
רҵ¿Î ÃâÒßѧ )RA
v[U1
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê K^]?@oHO
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell +H)!uLvaB
5. Fc¦Å receptor 6. Cytokine MYDf`0{$_a
¶þ¡¢ ÎÊ´ðÌâ wRV`v$*6
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 C)&gL=O*$
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ k2_6<v
Z
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ V\k5h
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 !~|"LA!jn
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠcd
ek^/
m
&3HFf
#cp$lt
Y
?v )"%.
' F 6au[
Q8DQ .C
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ [kp7LA"`
*mK);@pL
_Sk<S
רҵ¿Î ÃâÒßѧ <@x+N%C
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 654jS
!
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen {*ko=77$*
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin wNf*/?N
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test 3*2&Fw!B
9. Hybridoma technic 10.Mitogen (7Ca\H3$
11.Dentritic cell 12.Immunoproliferation R^u^y{ohr
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ 4Ow
Vt&
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ ~qLhZR\g^
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ#:ED 0</
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ i/O,`2
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ t#D\*:Xi
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ v-r[~
9V4V}[%
vS*0CR\
si
mX
Kz*AzB
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 82@;.%
{;z
L[AgCg
z_,]fd=o
רҵ¿Î ÃâÒßѧ x_H7=\pX]
Ò»¡¢ Ãû´Ê½âÊÍ ?BWvF]
p5/
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï iDkWW
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà ~E6+2t*
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ ,w58n%)H
¶þ¡¢ ÎÊ´ðÌâ e[k;SSs
1¡¢ TÁÜ°Íϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ j
n&9<"W
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁÜ°Íϸ°ûºÍЧӦÎïÖÊ¡£ X)R]a]1A
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆ乲ͬÌص㼰ÓëÁÙ´²µÄ¹Øϵ¡£ g7Q*KA+
4¡¢ ºÎνÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ buM>^A"
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØϵͳ£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ [@Fe
RIu8
kA:;c}p
[;LPeO
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ q2U"k
+&zuI
u(G;57ms
רҵ¿Î ÃâÒßѧ ,c %gwzU
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê ^l2d?v8
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR P;91C'T-x
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA mE@o27
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM v5bb|o[{K
¶þ¡¢ ÎÊ´ðÌâ C%o/
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌص㡣 }~,cCtg:o
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ l#f]KLv4N_
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖƵÄÒìͬµã¡£ n[S*gX0
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆ书ÄÜ¡£ ^aM/BS\
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ v&,VC~RN-J
gY^TBR0?m
H9m2Whq
{j4:.fD
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ NbMH@6%E
F7u%oLjr
^
/eSby
רҵ¿Î ÃâÒßѧ a9JJuSRC
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 3>3ZfFC
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule ]`U?<9~Ob
5. Autogous mixed lymphoyte reaction nE.s
¶þ¡¢ ÎÊ´ðÌâ I{UB!0H
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ wm[
d5A4
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ F9%VyQf
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ(D3m5fO
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹Øϵ£¿ A+*(Pds
5]ob;tAm
o6%f%:&
2;7GgO~
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ G2k71{jK
Rzj!~`&N
td$Jx}'A
רҵ¿Î ÃâÒßѧ bTKxv<
/'+JP4mK
e+aQ$1^t
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 'v)+S;oB
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance +& Qqu`)?F
5. Delayed type hypersensitivity [$+61n}.12
¶þ¡¢ ÎÊ´ðÌâ ;!Bkk9r"H
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ l8li@K
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ YR#1[fe*_
3. ¼òÊöHLAÓëҽѧµÄ¹Øϵ¡£ 6-}9m7# Y
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ"FD~XSRL
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠOnyq'
qA[}\8}h
3P>@ :
N|d@B{a(
I<#kw)W!
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ?!vW&KJZx
M](U"K?
U:(t9NX
b
רҵ¿Î ÃâÒßѧ Fv
B2y8&W
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê IHfqW?
1. hypersensitivity 2. cluster of differentiation sk/Mh8z
3. adhesion molecules 4. supper antigen 5. split tolerance BJTljg({o
¶þ¡¢ ÎÊ´ðÌâ @n3PCH6:Ao
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ RUO6Co-
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ {^iV<>J
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ n9ih^H
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ Po[zzj>m
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ Z
m>69gl
/xnhHwJm
0&@6NW&Mu
8iB}a\]B
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ R7>@-EG
רҵ¿Î ÃâÒßѧ 9`{cX
Ò»¡¢ Ãû´Ê½âÊÍ yDrJn*
r^
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å qK
pU.rP
5. GVHR 5irOK9hK
¶þ¡¢ ÎÊ´ðÌâ }I0^nv1
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷ÓᣠwO9<An
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌصãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ -_dgd:or
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌص㡣 Gy5W;,$q
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£
g$qh(Z_s
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ }9JPSl28Jr
!~#31kL&
[S%
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ I <7K^j+5:
6r`g+Js/
:d;5Q\C`
רҵ¿Î ÃâÒßѧ ,o`qB81
Ò»¡¢Ãû´Ê½âÊÍ w@4+&v>O
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å RDbA"e5
x
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ FWj~bn
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ ME(!xI//JZ
11. »ìºÏÁÜ°Íϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ .
T7ciD
Èý¡¢ ÎÊ´ðÌâ -p1arA
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ h(fh |R<
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ
J' ;tpr
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà p ,!`8c6
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ 9D
bp`%j
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ mnePm{
N\u-8nE5
JBqzQ^[n
=F`h2 A;a
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ `U1"WcN
`4o;Lz~
+$9w[ARN+
רҵ¿Î ÃâÒßѧ HTC7fS
Ò»¡¢Ãû´Ê½âÊÍ k$hWR;U
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó j6\{j#q
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁÜ°Íϸ°ûµÄ±íÃæ±êÖ¾ i|<*EXB"
Èý¡¢ ÎÊ´ðÌâ &I70ve
NY
1. ¼òÊöTÁÜ°Íϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ pyN PdEy
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ @{a(f;
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ sU8D;ML7
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ 3RD Q{&J:
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ T57S!CJ^$5
5=dg4"b]
m?csake.Me
OTRTa{TB
0I.7I#'3O
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ 2@ad! h
Ò»¡¢Ãû´Ê½âÊÍ }SYvGp{J,
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï {U4%aoBd8
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó G~_dSa@g G
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ A_[65'*b
¶þ¡¢ ÎÊ´ðÌâ 9;@6iv
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ `527vK
6
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ L.8-nTg"y
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ Tx!mW-Lt
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ ^@N@gB
I|p(8R!
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ )37|rB E
Ò»¡¢ Ãû´Ê½âÊÍ `=FfzL
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ nTLdknh"
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ SL*B `P~{
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© Jo2:0<VL
10¡¢ ÒõÐÔÑ¡Ôñ %=GnGgu
¶þ¡¢ ÎÊ´ðÌâ E")82I
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 chxO*G
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ &